Hematologists take note ⬇️⬇️ DAT negative hemolysis, thrombocytopenia, transaminitis and a fever =

Probably not. RWE for Idarucizumab use for bleeding in Ontario (also Denmark and Sweden) showed numerically higher mortality (almost double) compared to REVERSE-AD sciencedirect.com/science/articl…

What to do with an ICH patient who bled while on AC for a mechanical heart valve? When and how to restart AC? This is a cool study showing that the risk of bleeding complications far outweighs the risk of thromboembolism overall Plus the risk of ICH is highest when IV heparin

Thank you Ontario Health OLMP, thank you Dynacare, thank you LifeLabs, thank you AlphaLabs, thank you University of Toronto, thank you to all members of ‘Raise the Bar’. This is a big step forward for Ontario and for 🇨🇦 Canada in promoting health equity for ppl with iron deficiency. 💥

Very pleased to see this in the mail today! Congrats to Michelle Sholzberg and team in bringing impactful change after years of advocacy and hard work. LifeLabs

The study (GABA-WHY) ran during his fellowship with the help of Iman Huseen and Kristen Moran, our amazing research assistants. It's published today in JAMA Internal Medicine Briefly, by giving patients these brochures, we increased deprescribing by 13%! jamanetwork.com/journals/jamai…

FcRn-targeting drugs are the new kid on the immuoheme block with many realized and potential uses in Heme and Transfusion patients Co-authors Brian Adkins Jeremy et al have written an incisive review on the present and future of FcRn agents AmericanJournalofHematology doi.org/10.1002/ajh.27…

Great presentation by Dr. Ryan Kerzner 🇨🇦 on the importance and relevance of Anticoagulation Forum Stewardship in Canada. Approx 65% of admitted patients need anticoagulation adjustments (type , dose), de-prescription of anti-platelets, etc. Avoiding complications and improving outcomes

The KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD) is available for public review through Friday, November 22. You can download the public review draft and share comments via the feedback survey on the KDIGO Anemia in CKD Guideline Website:

1/ FDA hearing on #andexanet alfa is tomorrow (21 Nov 2024). The documents contain some more data on thrombotic events that weren't published in ANNEXA-I. To be honest, reading through, I have found this data pretty shocking. A 🧵

👇🏻👇🏻👇🏻 Important key data re annexa-I

FDA's own review of thrombotic events reported 12 extra cases – 9 in andexanet & 3 in usual care – that were not assigned as thrombotic by blinded committee. Sorry, I don’t have more info on this! Final figures (based on n=471 FDA safety set): 14.6% vs 6.9%, stroke 5% vs 0.4%.

Thrombosis rates are much higher in patients receiving high dose andexanet (as are death rates - more on efficacy in next thread)

Almost 120 years since Thomas McCrae (younger brother of LCol. John🇨🇦) described these cytoplasmic inclusions known today as Aeur rods. My yearly plea for morphologists to rename them. Auer rods or McCrae rods? - Barbara J. Bain AJH onlinelibrary.wiley.com/doi/full/10.10… David Steensma, MD

On International Day of Women and Girls in Science, learn about a unique, women-founded, multidisciplinary clinic at St. Michael’s that provides treatment, care, support and education for women with bleeding disorders – and their babies. unityhealth.to/2025/02/multid…

Our recent study (a global collaboration) McMaster University Department of Medicine MCTransfusionR NEJM McMaster Platelet Immunology Laboratory McMaster Biochemistry & Biomedical Sciences McMaster IIDR McMaster Health Sciences McMaster University VITT-like Monoclonal Gammopathy of Thrombotic Significance | New England Journal of Medicine nejm.org/doi/full/10.10…

“we found that the M protein was the VITT-like antibody” so cool

Three cured #sicklecell persons in one room this am. #haplobmt. Never thought I'd see the day.

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Hot off the press! COBBRA trial showed that apixaban is associated with >50% reduced risk of clinically-relevant bleeding symptoms for acute VTE treatment. This can be practice changing! Lana Castellucci Marc Rodger CanVECTOR Network